In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
Webinar Date/Time: Thu, Jun 1, 2023 11:00 AM EDT
This study aims to evaluate harvest strategies and metabolite-based cell density estimation methods for Lentivirus production with HEK293T cells.
Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT
Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST Why would a CDMO to leverage fixed-bed bioreactor technology to develop and produce GMP lentiviral vectors? Join us for a discussion on increasing quality and decreasing time and cost to accelerate time to clinic and market for lentiviral products with technology.
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.